Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, González Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Yost SE, Yuan Y, Chen ZJ, Fu YX, Hanker AB, Arteaga CL. Lee KM, et al. Among authors: malladi vs. Cancer Immunol Res. 2022 Jul 1;10(7):829-843. doi: 10.1158/2326-6066.CIR-21-0826. Cancer Immunol Res. 2022. PMID: 35561311 Free PMC article.
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. Zhang Z, et al. Among authors: malladi vs. Cancer Cell. 2020 Apr 13;37(4):584-598.e11. doi: 10.1016/j.ccell.2020.03.001. Epub 2020 Mar 26. Cancer Cell. 2020. PMID: 32220301 Free PMC article.
Identification and characterization of an alternative cancer-derived PD-L1 splice variant.
Hassounah NB, Malladi VS, Huang Y, Freeman SS, Beauchamp EM, Koyama S, Souders N, Martin S, Dranoff G, Wong KK, Pedamallu CS, Hammerman PS, Akbay EA. Hassounah NB, et al. Among authors: malladi vs. Cancer Immunol Immunother. 2019 Mar;68(3):407-420. doi: 10.1007/s00262-018-2284-z. Epub 2018 Dec 18. Cancer Immunol Immunother. 2019. PMID: 30564890 Free PMC article.
Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.
Kapur P, Gao M, Zhong H, Chintalapati S, Mitui M, Barnes SD, Zhou Q, Miyata J, Carrillo D, Malladi VS, Rakheja D, Pedrosa I, Xu L, Kinch L, Brugarolas J. Kapur P, et al. Among authors: malladi vs. Mod Pathol. 2022 Mar;35(3):333-343. doi: 10.1038/s41379-021-00896-6. Epub 2021 Sep 20. Mod Pathol. 2022. PMID: 34538873 Free PMC article.
Perivascular mesenchymal cells control adipose-tissue macrophage accrual in obesity.
Shan B, Shao M, Zhang Q, Hepler C, Paschoal VA, Barnes SD, Vishvanath L, An YA, Jia L, Malladi VS, Strand DW, Gupta OT, Elmquist JK, Oh D, Gupta RK. Shan B, et al. Among authors: malladi vs. Nat Metab. 2020 Nov;2(11):1332-1349. doi: 10.1038/s42255-020-00301-7. Epub 2020 Nov 2. Nat Metab. 2020. PMID: 33139957 Free PMC article.
Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
Udden SN, Wang Q, Kumar S, Malladi VS, Wu SY, Wei S, Posner BA, Geboers S, Williams NS, Liu Y, Sharma JK, Mani RS, Malladi S, Parra K, Hofstad M, Raj GV, Larios JM, Jagsi R, Wicha MS, Park BH, Gupta GP, Chinnaiyan AM, Chiang CM, Alluri PG. Udden SN, et al. Among authors: malladi vs. JCI Insight. 2022 Sep 8;7(17):e151851. doi: 10.1172/jci.insight.151851. JCI Insight. 2022. PMID: 35881485 Free PMC article.
58 results